


Scientific Resume / autobiography

A. PERSONAL DETAILS			
1. Full name, ORCID and Google scholar accounts: Mina Thabet Gayed Kelleni https://orcid.org/0000-0001-6290-6025 https://scholar.google.com/citations?user=TZcfzCQAAAAJ&hl=en			
2. Citizenship and Religion: Egyptian, Christian			
3. Marital status and children: Married and blessed with three children.			
4. Cellphone: (+20) 1200382422			
5. E-mail: drthabetpharm@yahoo.com, mina.kelleni@mu.edu.eg			
6. Date of birth (day/month/year): 01/10/1981		7. Place of birth (City and Country): Minya, Egypt	
8. Current residential address: Shalaby district, Minya, Egypt.			
B. EDUCATIONAL QUALIFICATIONS AND INTERESTS			
9. Field of study/discipline and specialization: Medicine, Pharmacology			
10. Tertiary academic qualifications:			
Degrees/diplomas obtained/underway	Field of study	Institution & location	Completion date
MBBS (Hons) WES ECA Canadian Equivalent verified January 2020	Medicine and Surgery	College of Medicine, Minia University, Egypt	February 2005
MSc (Pharmacology) WES ECA Canadian Equivalent verified January 2020	Basic Medical Sciences - Pharmacology	College of Medicine, Minia University, Egypt	February 2011 February 2016
MD/PhD (Pharmacology) WES ECA Canadian Equivalent verified January 2020			
C. EMPLOYMENT HISTORY			
11. Employment experience:			
Name of employer & address	Position	Dates of employment	
College of Medicine, Minia University, Egypt	Demonstrator of Pharmacology	April 2006 to March 2011	
Al-Shefa Medical Center, Cairo, Egypt	General Practitioner and Dermatologist	March 2006 to December 2012	
Al-Muhaish Dispensary,	Practicing Dermatologist	Jan 2013 to December 2013	

Alhasa, Eastern province, KSA	(Saudi Board Certified, Dermatology SCFHS, KSA MOH Licensed)	
College of Medicine, Minia University, Egypt	Lecturer of Pharmacology	March 2011 to February 2016
College of Medicine, Minia University, Egypt	Assistant Professor of Pharmacology	March 2016 to date
College of Medicine, Minia University, Egypt	Associate Professor of Pharmacology	My promotion was supposed to be appointed in <u>February 2021</u> , just like my peers. However, it was denied because the person in charge of promotion prohibited me from delivering my papers to be considered for promotion as he believed that COVID-19/ clinical pharmacology research is less important than experimental research and shouldn't be considered at all. I won a judiciary case in <u>October 2023</u> and finally I've been able to deliver my papers for consideration in March 2024 and in December 2024 two of three members of the committee decided to deny me the promotion as they don't consider my COVID publications as a research. The third professor has highly applauded the significance of my published research articles. I've filed a new judiciary case in March 2025. I consider it a real blessing to fight to secure the future of clinical pharmacology in Egypt.

College of Medicine, Jouf University, KSA	Assistant Professor of Pharmacology and Clinical Skills	February 2018 to August 2019
College of Pharmacy, Jouf University, KSA	Assistant Professor of Pharmacology, Toxicology, Anatomy, Physiology and Pathophysiology	August 2019 to August 2020

12. Other professional honors, editorial board/ reviewer membership:

Included in **Stanford University/ Elsevier World's Top 2% Most Cited Scientists** in its list published in **2022, 2023 and 2024**.

Two of my published COVID-19 papers have been linked to the **United Nations SDGs "for helping to tackle some of the world greatest challenges"**.

Research fellow of INTI International University, Malaysia (June 2023).

Founder of the Egyptian and African Kelleni's COVID-19 and Antiviral Protocol; an early Immunomodulatory Management Protocol safely and effectively used, since April 2020, to manage COVID-19 patients as well as RSV, Influenza and Norwalk viral infections in pediatric, adult, and pregnant patients.

Founder of Kelleni's COVID Clinic, the first in a region/continent and probably one of the pioneers globally to be dedicated to manage patients suffering from COVID-19 both through the traditional medical examination as well as telemedicine.

Founder of Kelleni's Post/Long COVID and Tinnitus clinic, the first in a region/continent and probably one of the pioneers globally to be dedicated to manage patients suffering from Post COVID Syndrome/ Long COVID and Tinnitus through the traditional medical examination as well as telemedicine.

Founder of the first Pharmacology Clinic in Egypt and probably one of the pioneers globally helping patients suffering from different unresolved diagnoses in all medical specialties and those who are suffering multiple comorbidities belonging to multiple medical specialties to personalize their optimal pharmacotherapy. It also has a community activity in raising public and physicians' awareness about pharmacovigilance, adverse drug reactions and drug-drug interactions.

Practicing senior consultant of Pharmacology; the Egyptian Syndicate of Physicians (the first in Egypt).

Member of College of Medicine, Minia University Council of Scientific Research (October 2023).

Inventor and one of the holders of the international copyright EC-01-002984 "Novel

neurological drug of combined valproic acid and topiramate” and **EC-01-002980** “Topical use of berberine in treatment of male sexual disorders such as premature ejaculation and/or erectile dysfunction” (internationally registered by INTEROCO copyright office, October 2020) and is currently and recently officially distributed, after SFDA approval, in the pharmacies of KSA (**PLAZMID gel**) as a cosmetic massage gel waiting for further studies to be labeled therapeutic. Notably, **both the international copyrights had local patent applications in KSA. Notably, Plazmid gel has been exported from KSA to individuals living in several European Union countries, Canada, Japan as well as many Arab countries.**

Discussions with the Egyptian Ministry of Higher Education to establish an industrial collaboration for the manufacturing and export of PLAZMID gel and a unique nutraceutical aimed at enhancing natural immunity against SARS CoV-2 and other respiratory viruses. (Link to the official post: <https://www.facebook.com/MOHESREGYPT/posts/pfbid02XoLeC1gGB4s77YRRPGTypUQp5iabsViPvBgf95p9e5qHjxwaxtiQFzt9dCpG8wFgl>).

Academic supervisor of post graduate physicians and researchers who worked and are working to fulfill the requirements to obtain their MSc and PhD degrees in pharmacology.

Keynote speaker at 35th World Congress on Pharmacology on August 01-02, 2022 Rome, Italy theming Exploring new Horizons in Pharmacology: Drug Discovery Design & Development with a title of: “Personalized Expanded Kelleni’s Immunomodulatory COVID-19 Protocol Safely Used to Manage Severe COVID-22: A Case Report”.

Plenary speaker at the Virtual World Healthcare Conference & Expo (WHC22) on the 15th of to April 2022 with a title of: "Recent Western Updates in COVID-19 Pharmacotherapy (January - April 15, 2022): An Eastern Afro-Egyptian Perspective”.

Key speaker at the Virtual World Healthcare Conference & Expo (WHC21) on the 15th of to April 2021 at session: “New Health Informatics, Healthcare Transformation, Telehealth and Telemedicine” with a keynote title of: "Could COVID 19 Flourished Telemedicine Lead the World Towards Virtual Health Care Facilities?”.

Speaker at the 2nd edition of the Webinar on Corona & Infectious Diseases presenting: “NSAIDs/ Nitazoxanide/ Azithromycin Immunomodulatory Protocol Used in Adult, Geriatric, Pediatric, Pregnant, and Immunocompromised COVID-19 Patients: A Real-World Experience” held on 26-27 July 2021.

Youssef Jameel prize for scientific excellence awarded through the Egyptian Society of Pharmacology and Experimental Therapeutics (ESPET) (March 2010).

I have been invited as a speaker to tens of international medical conferences and to serve as an organizing committee member of numerous international medical conferences all over the world.

I've acted as a **member of the editorial boards of several international medical journals specialized in general medicine, endocrinology and pharmacology** e.g. General Medicine, open access as well as in Integrative Obesity and Diabetes where I managed manuscript submissions, coordinated peer review, and made final recommendations on publication. I have also contributed as an editorial board member for several other journals e.g. Journal of Clinical Research; Acute and Chronic Disease Reports; JOURNAL OF EMERGING AND RARE DISEASES; Current Trends in Metabolomics; Open Access Journal of Endocrinology; Gastroenterology Pancreatology and Hepatobiliary Disorders; Journal of Molecular Genetics and Gene Research.

I've also acted a research grant agency reviewer for Health Research Council of New Zealand and as a reviewer for several international medical journals e.g. Biomedicine & Pharmacotherapy; Expert Review of Anti-Infective Therapy; Expert Review of Clinical Immunology; British journal of pharmacology; Clinical Pharmacology & Therapeutics; Basic & Clinical Pharmacology & Toxicology; The Lancet's EClinicalMedicine; Journal of General Internal Medicine; Clinical Case Reports; All Life; Expert Review of Clinical Pharmacology; Virology Journal; World Journal of Virology; World Journal of Clinical Infectious Diseases; Human Vaccines & Immunotherapeutics; Frontiers in Pharmacology; Frontiers in Immunology; BMJ Open; PLOS ONE; Current Research in Pharmacology and Drug Discovery; Therapeutic Advances in Infectious Disease; Therapeutic Advances in Respiratory Disease; Experimental and Therapeutic Medicine; Clinical Chemistry and Laboratory Medicine; Indian Journal of Pharmacy and Pharmacology; International Research Journal of Medicine and Medical Sciences; Pharmacy & Pharmacology International Journal; Current Trends in Pharmacology and Clinical Trials Journal; Journal of Unexplored Medical Data; Diabetes & Obesity International journal; Journal of General and Emergency Medicine; and Pediatric Research and Child Health.

13. English Language Certificates

IELTS (computer based) overall 7.5/9; Listening 8, Reading 9, Writing 6.5, Speaking 7 (July 2019; First and only attempt).

TOEFL (iBT) overall 104/120; Reading 24 Listening 28 Speaking 24 Writing 28 (February 2010, First and only attempt).

14. Academic experience, administrative service experience, research interests and teaching philosophy:

I've taught almost all courses of basic, clinical, experimental pharmacology and pharmacotherapy through the traditional, credit hours as well as the integrated/interdisciplinary Problem-Based Learning (PBL) and Team-Based Learning (TBL) methods in Egypt and KSA to under as well as post graduate students of medicine, dentistry, and nursing colleges.

Besides pharmacology, I've also taught **clinical pharmacy (pathophysiology I and II), anatomy and physiology** through the credit hours learning system to pharmacy college undergraduate students in KSA.

Academic supervisor of post graduate physicians and researchers.

During COVID-19 pandemic, I have mastered Blackboard®-based virtual teaching and examinations.

My philosophy is simple; help the future physicians and scientists to be clinically oriented and patient centered while providing them with a spirit of scientific adventure while studying pharmacology.

I believe teaching is a gift that is nourished by practice and dedication. Through the years, I've built a reputation among students delivering the sophisticated knowledge in a simplified, yet highly scientific manner and I've been so fortunate to be praised by hundreds of them, now amazing physicians, dentists, pharmacists and nurses. I've also been so keen to develop my personal clinical capabilities as much as I can to remain updated in practice as well as to provide the highest possible quality of education to my students. Thus, in teaching pharmacology and basic medical science various disciplines, I've always adopted a clinical approach to make the future health care professionals love the subject.

I've always focused on the basics when teaching to undergraduate students and on the challenges when teaching to postgraduate ones. Once a tutor, always a tutor is a famous proverb, yet it should be modified, once a tutor, always a learner and it's of utmost importance to implant in the soul of our students not to abandon learning and to continue updating their knowledge after graduation to ensure the best medical practice is provided.

In college of medicine, Minia University, I'm the pharmacology department internal coordinator of the endocrine and reproductive systems block for five consecutive

years.

In college of medicine, Jouf University that fully adopted integrated PBL and TBL methods in teaching medicine, besides teaching pharmacology in all blocks and **facilitating PBL, TBL, and seminars sessions with other colleagues from different disciplines**, I've also actively participated in **teaching and demonstrating clinical skills**, sharing with other professors of different specialties, to the students.

I've also presented two seminars entitled: "Drug-induced Malignancy" and "Drug Design: The Future of Pharmacotherapy" at the college's scientific meetings and I have actively participated at the college's second international meeting "Maternal and Child Health" and **I have mentored a student research group** who examined the use of the use of antidiabetic drugs at a tertiary diabetes center at Al-Qurriyat, Jouf province, KSA.

In college of pharmacy, Jouf University, I was responsible for the courses of **clinical pharmacy (pathophysiology I and II), anatomy and physiology together with my duty to teach pharmacology** and I have been a member of scientific jury that evaluated the students' research activities and graduation projects at the college's scientific day.

In college of medicine, Minia University, I was one of three staff faculty members who were responsible to prepare and finalize the required faculty files of the parameter: "leadership and governance" **submitted to and approved by the Egyptian national authority for quality assurance and accreditation of education**. **I've also been selected, October 2023, as a member of college of Medicine, Minia University Council of scientific research.**

In college of medicine, Jouf University, I've been involved in **many administrative committees** e.g., head of policies and procedures committee, member of both quality and accreditation unit as well as examination committee. I've also served as a **block co-organizer** in both "growth and development" as well as "musculoskeletal" blocks and shared in revising as well as updating the matrix, course specifications, ILOs and content of several blocks and courses.

In college of pharmacy, Jouf University, I've been selected among the small teamwork preparing for its national and international accreditation and **participated in a meeting with Accreditation Council for Pharmacy Education (ACPE)** and participated in an international virtual meeting with its director, Dr. Michael J. Rouse.

I've practiced general medicine, internal medicine, endocrinology, as well as general and aesthetic dermatology since my 2006 graduation in my own clinic, various dispensaries, and hospitals in Egypt, KSA and I've served numerous patients of several nationalities through telemedicine and my clinic.

I'm researching in pharmacology and medicine since 2006; my MSc thesis was entitled: "Effect of nitro-aspirin versus ezetimibe in experimentally induced fatty liver in rats" and the PhD/MD thesis was entitled: "Effect of some antioxidant, antihypertensive and antidiabetic drugs on the toxicity of some antineoplastic drugs in rats".

I'm interested in the pursuit to discover novel pharmacotherapeutics of COVID-19, Post COVID syndrome, regenerative medicine, stem cell therapy, epilepsy, premature ejaculation, diabetes, obesity, NAFLD, cancer, autoimmune diseases, and auto-inflammatory diseases **while searching for novel pathophysiological approaches**. Both short and long term research plans would interact depending on the available resources.

15. Relevant copyrights, academic papers, and other medical publications:

Copyrights

Mina T. Kelleni (author, inventor), Mohammed J. Alenzi, Mohammed H. Elkomy (2020): Topical use of berberine in treatment of male sexual disorders such as premature ejaculation and/or erectile dysfunction. International Copyright: EC-01-002980. Saudi Patent Application Number: 119410090. Currently available in the Saudi pharmacies (PLAZMID gel), SFDA license number: CN-2023-373373.

Mina T. Kelleni (author, inventor), Khalid S. Alharbi, Mohammad M. Al-Sanea (2020): Novel neurological drug of combined valproic acid and topiramate. International Copyright: EC-01-002984. Saudi Patent Application Number: 119410122.

COVID-19 published manuscripts

Mina T. Kelleni (2025): Kelleni's protocol incorporating non-steroidal anti-inflammatory drugs and nitazoxanide to early manage dengue virus disease: An antiviral silver bullet. *World J Clin Cases* 2025; 13(28): 108181 [DOI: 10.12998/wjcc.v13.i28.108181].

Mina T. Kelleni (2025): Real-life practice of Kelleni's protocol in treatment and post exposure prophylaxis of SARS-CoV-2 HV.1 and JN.1 Subvariants. Peer-reviewed and accepted to be published as a field of vision at World Journal of Virology.

Mina T. Kelleni (2025): What would Hippocrates have sworn upon witnessing the COVID-19 mandates and mortality paradox. *World J Exp Med* 2025; 15(1): 98575 DOI: 10.5493/wjem.v15.i1.98575

Mina T. Kelleni (2025): Could the next “disease X” be a pandemic of virus-induced encephalitis? What should our first medical response be? Expert Review of Anti-Infective Therapy. DOI: <https://doi.org/10.1080/14787210.2024.2432277>

Q1 Journal, Impact Factor 4.2

Mina T. Kelleni (2024): Angiotensin receptor blockers could be superior to angiotensin-converting enzyme inhibitors in COVID-19 management: the potential role of bradykinin. Irish Journal of Medical Science. DOI: <https://doi.org/10.1007/s11845-024-03679-5>.

Q2 Journal (Scopus), Impact factor: 2.1

Mina T. Kelleni (2024): COVID-19 mortality paradox (United States vs Africa): Mass vaccination vs early treatment. World J Exp Med 14(1): 88674. DOI: [10.5493/wjem.v14.i1.88674](https://doi.org/10.5493/wjem.v14.i1.88674).

Mina T. Kelleni (2024): Repurposing metformin to manage idiopathic or long COVID Tinnitus: self-report adopting a pathophysiological and pharmacological approach, Inflammopharmacology, DOI: <https://doi.org/10.1007/s10787-023-01421-8>. PMID: 38294616

Q1 Journal, Impact Factor 5.8

Mina T. Kelleni (2023): The African Kelleni’s Roadmap Using Nitazoxanide and Broad Spectrum Antimicrobials to Abort Returning to COVID-19 Square One. Inflammopharmacology, DOI: <https://doi.org/10.1007/s10787-023-01263-4>. PMID: 37326756.

Q1 Journal, Impact Factor 5.8

Mina T. Kelleni (2023): SARS CoV-2 Genetic Jump to a New SARS CoV-3 Pandemic: Let’s Be Prepared. Journal of Infection, DOI: <https://doi.org/10.1016/j.jinf.2023.03.018>. PMID: 36958637.

Q1 Journal, Impact Factor 28.2, Ranked 3/96 globally in the category of Infectious Diseases.

Mina T. Kelleni (2023): Real-world practice of the Egyptian Kelleni’s protocol amid changing tropism of SARS-CoV-2 omicron BA.5.2.1.7, XBB 1.5 and CH.1.1 subvariants: a multi-purpose protocol. Inflammopharmacology, DOI: <https://doi.org/10.1007/s10787-023-01180-6>. PMID: 36928633. **Q1 Journal, Impact Factor 5.8**

Mina T. Kelleni (2023): Evolution of SARS CoV-2 Omicron Subvariants BF.7 and XBB.1.5: Time to follow Africa and abort all COVID Restrictions. Journal of Infection, DOI: <https://doi.org/10.1016/j.jinf.2023.01.027>. PMID: 36702311.

Q1 Journal, Impact Factor 28.2, Ranked 3/96 globally in the category of Infectious Diseases.

Mina T. Kelleni (2022): Real-life Practice of the Egyptian Kelleni's Protocol in the Current Triple-demic: COVID-19, RSV and Influenza. Journal of Infection. DOI: <https://doi.org/10.1016/j.jinf.2022.12.007>. PMID: 36513168.

Q1 Journal, Impact Factor 28.2, Ranked 3/96 globally in the category of Infectious Diseases.

Mina T. Kelleni (2021): NSAIDs and Kelleni's protocol as potential early COVID-19 treatment game changer: could it be the final countdown? InflammoPharmacology. DOI: [10.1007/s10787-021-00896-7](https://doi.org/10.1007/s10787-021-00896-7). PMID: 34822026. **Q1 Journal, Impact Factor 5.8**

Mina T. Kelleni (2021): NSAIDs/Nitazoxanide/Azithromycin Repurposed for COVID-19: Potential Mitigation of the Cytokine Storm Interleukin-6 Amplifier via Immunomodulatory Effects. Expert Review of Anti-infective Therapy. DOI: [10.1080/14787210.2021.1939683](https://doi.org/10.1080/14787210.2021.1939683). PMID: 34088250

Q1 Journal, Impact Factor 4.2

Mina T. Kelleni (2021): COVID-19, Ebola virus disease, and Nipah virus infection reclassification as novel acute immune dysrhythmia syndrome (n-AIDS): potential crucial role for immunomodulators. Immunologic Research 69: 457–460. DOI: [DOI: 10.1007/s12026-021-09219-y](https://doi.org/10.1007/s12026-021-09219-y). PMID: 34357535

Q2 Journal, Impact Factor 4.4

Mina T. Kelleni (2021): Resveratrol-Zinc Nanoparticles or Pterostilbene-Zinc: Potential COVID-19 Mono and Adjuvant Therapy. Biomedicine & Pharmacotherapy 139: 111626. PMID: 33894625

Q1 Journal, Impact Factor 7.5

Mina T. Kelleni (2021) BCG vaccination potential for COVID-19: an analytical approach, *Human Vaccines & Immunotherapeutics*, DOI: 10.1080/21645515.2021.1885281 PMID: 33769207

Q1 Journal, Impact Factor 4.8

Mina T. Kelleni (2021): Tocilizumab, Remdesivir, Favipiravir, and Dexamethasone Repurposed for COVID-19: a Comprehensive Clinical and Pharmacovigilant Reassessment. *SN Comprehensive Clinical Medicine* 3, 919–923. DOI: 10.1007/s42399-021-00824-4. PMID: 33644693

Mina T. Kelleni (2021): NSAIDs/ Nitazoxanide/ Azithromycin Immunomodulatory Protocol Used in Adult, Geriatric, Pediatric, Pregnant, and Immunocompromised COVID-19 Patients: A Real-World Experience. *Canadian Journal of Medicine* 3: 121-143.

Mina T. Kelleni (2021): Sars CoV-2 Vaccination Autoimmunity, Antibody Dependent Covid-19 Enhancement and Other Potential Risks: Beneath the Tip of The Iceberg. *International Journal of Pulmonary & Respiratory Sciences*. 5(2): 555658. 10.19080/IJOPRS.2021.05.555658

Mina T. Kelleni (2020): Early use of Non-steroidal anti-inflammatory drugs in COVID-19 might reverse pathogenesis, prevent complications and improve clinical outcomes. *Biomedicine & Pharmacotherapy*. 133: 110982-110982 DOI: 10.1016/j.biopha.2020.110982 PMID: 33197762

Q1 Journal, Impact Factor 7.5

Mina T. Kelleni (2020): ACEIs, ARBs, ibuprofen originally linked to COVID-19: the other side of the mirror. *Inflammopharmacol* 28, 1477–1480. DOI: 10.1007/s10787-020-00755-x PMID: 32920716

Q1 Journal, Impact Factor 5.8

Mina T Kelleni (2020): SARS CoV-2 viral load might not be the right predictor of COVID-19 mortality. *Journal of infection*. 82(2): E35. DOI: 10.1016/j.jinf.2020.08.018 PMID: 32810520

Q1 Journal, Impact Factor 28.2, Ranked 3/96 globally in the category of Infectious Diseases.

Mina T Kelleni (2020): Nitazoxanide/Azithromycin combination for COVID-19: A suggested new protocol for COVID-19 early management. *Pharmacological Research*. 157: 104874. DOI: 10.1016/j.phrs.2020.104874 PMID: 32360581

Q1 Journal, Impact Factor 9.3

Mina T Kelleni (2020): "Remdesivir-Gate for COVID-19". *Acta Scientific Gastrointestinal Disorders* 3.8: 01

Kelleni M.T. (2020) "Rapid Response: Remdesivir is least likely to be effective for safe treatment of COVID-19: A pharmacovigilant point of view". *British Medical Journal* 369: m2097rr.

Clinical and experimental pharmacology published manuscripts

Marly Nady Adly, Walaa Yehia Abdelzaher, **Mina Thabet Kelleni**, Mina Ezzat Attya, Mohamed Abdellah Ibrahim (2024): Effect of hepatic ischemia reperfusion on testicular tissue in rats. *Minia Journal of Medical Research*. DOI: 10.21608/mjmr.2024.292934.1716

Mahrous Abdelbasset Ibrahim, Ibrahim Abdelkhalek Albahlol, Farooq Ahmed Wani, Ahmed Abd-Eltawab Tammam, **Mina Thabet Kelleni**, Mohammed Ubaidullah Sayeed, Noha M Abd El-Fadeal, Alaa Abdelhamid Mohamed (2021): Resveratrol Protects against Cisplatin-induced Ovarian and Uterine Toxicity in Female Rats by Attenuating Oxidative Stress, Inflammation and Apoptosis. *Chemico-Biological Interactions* 338: 109402. PMID: 33587916.

Q1 Journal, Impact Factor 5.1

Athar M Khalifa, **Mina T Kelleni**, Mahrous A Ibrahim, Medhat M Farag, Gamal A Bakhaat (2020): Protective Effects of Blackberry Juice against Cisplatin-Induced Testicular Toxicity in Rats: Up-Regulation of Bcl-2 Proteins and Androgen Receptors; *International Medical Journal* 27(5): 584-589.

Mahrous A Ibrahim, Farooq A Wani, Athar M Khalifa, **Mina T Kelleni**, Marwa M Anwar, Ashok kumar, Mohammed S Ubaidulla (2019): Protective effects of selenium on malathion-induced testicular toxicity in mice. *Indian Journal of Animal Research* 54(3): 335-341.

Mina T Kelleni (2019): Embrace the Future of Drug Therapy of Diabetes Mellitus: Five Novel Approaches with Remarkable Potentials. *Biomed J Sci & Tech Res* 13(2)-2019.

Kelleni MT (2018): Role of central and peripheral serotonin in obesity: what to expect in the near pharmacotherapy future? *Adv Obes Weight Manag Control*. 8(6):291.

Kelleni MT (2018): Drug induced malignancy: a focus on pioglitazone. *Pharm Pharmacol Int J*. 6(4):296–298.

Mina T Kelleni (2018): Betaine potentials to prevent diabetes and diabetic complications: what hindered the favorable clinical trial outcomes and what to do? *Diabetes Obes Int J* 3(3): 000815.

Mina T Kelleni (2018): Vitamin D link to diabetes and obesity: Interesting promising and opposing results to be followed up. *Curr Res Diabetes Obes J* 8(1): CRDOJ.MS.ID.555734

Kelleni MT (2018): Using subcutaneous insulins to manage mild to moderate diabetic ketoacidosis: a simpler protocol that may save millions in the developing world. *Open Access J Endocrinol* 2(3): 000128.

Mina T Kelleni (2018): Pioglitazone: An Ongoing Misery in the Developing Countries to Which I can't be Pragmatic!. *J Endocrinol* 2(2): 000122.

Kelleni MT (2018) HCV Infection in Pediatric Population A Current Brief Synopsis. *Pediatr Res Child Health* 1: 001-001.

Mina T Kelleni (2018): Using insulin glargine temporarily to control resistant hyperglycemia induced by mild to moderate bacterial infections in Egyptian type 2 diabetic out patients. A real life experience. *Gen Med (Los Angeles)* 6(1): e116.

Mina T Kelleni (2018): Back to oral hypoglycemic drugs after ten years of insulin injections; An Egyptian case study. *J Clin Exp Endocrinol* 2(1): e105

Mina T Kelleni (2017): Sublaboratory hypothyroidism in Egyptian young adult females with normal TSH levels; what to do? A practical real life experience. *J Gen Emerg Med* 2(6): 102e.

Kelleni MT (2017): Diabetogenic Drugs and Hormones, what Every Physician should know and be Aware of? *Gen Med (Los Angeles)* 5: e114.

Mina T Kelleni (2017): Autoimmune Cholangiopathy at a Glance: Diagnosis, Differential Diagnosis and Treatment. *Acute Chronic Dis*,1:1. 1000e102.

Mina T Kelleni (2017): Idiopathic Hypereosinophilic Syndrome: Etiology, Diagnosis, Manifestations and Management. *J Endocrinol Thyroid Res.* 2017; 2(3): 555586.

Mina T. Kelleni (2017): Islet Cell Transplantation for Treating Type 1 Diabetes: The Bright Future of Drug Designing and Development. *Nov Appro Drug Des Dev* 1(3): NAPDD.MS.ID.555564

Kelleni MT (2017): How the brain-gut axis may connect several cerebro-intestinal comorbidities: Irritable bowel syndrome and Epilepsy as examples? ***Int J Gen Med Surg* 1(1): 1-3.**

Mina T Kelleni (2017): Benefits of green coffee beans extract in health and obesity. *SF Obesity Res J* 1:1.

Mina T. Kelleni (2017): Avian flu suspected upcoming pandemic: prevention and management. *SF J Flu Sci* 1:1.

Kelleni MT (2017): Use of Insulin Glargine and Metformin for Prevention of Diabetes and its Cardiovascular Complications. *Diabetes Obes Int J* 2(2): 000148.

Ibrahim S, Kamel MY, **Kelleni MT** (2017): Effect of nifedipine and glibenclamide addition in a model of high fat diet induced hypertension and hyperlipidemia in rabbits receiving donepezil. *Int J Sci Res Environ Sci Toxicol* 2(1): 4.

Mina T. Kelleni (2017): Type 2 Diabetes Mellitus: a reciprocal mutual interaction with amyloidosis or a presentation of an isolated primary pancreatic amyloidosis? *Integr Obesity Diabetes*, 3(1): 1-2. doi: 10.15761/IOD.1000165

Kelleni MT (2017): General Medicine, Open Access: A Wonderful 2016 Harvest and New Heights to Look Forward In 2017. Gen Med (Los Angeles) 5:1000e112.

Mina T. Kelleni (2016): Gliflozins: initial review of literature. Integr Obesity Diabetes 2(5): 276-276. DOI: 10.15761/IOD.1000159

Mina T. Kelleni (2016): Pre-Dorsal Myxedema: A Rare Unique Manifestation of Hypothyroidism in an Egyptian Female Patient. J Gen Emerg Med 1(1): 101e.

Mina T Kelleni (2016): Sofosbuvir/Simeprevir Induced Fatal Thrombocytopenia in a 47 Years Old Egyptian Patient. Gen Med (Los Angeles) 4:e111

Kelleni MT (2016): A rapid and successful corticosteroid based approach used to treat resistant Alopecia Areata Sisaipho in a 7 years old Egyptian girl; when pediatrics equals grace. Ped Health Res. 1:1.

Mina TK (2016): Amyloid Deposits: a Possible Link between Type 2 Diabetes Mellitus and Cancer. Diabetes Obes Int J 1(6): 000131.

Kelleni MT (2016): Rituximab: Is it Possible to Link Both Autoimmune Haemolytic Anemia and Aplastic Anemia Regarding the Etiology and Management? Gen Med (Los Angeles) 4:e110. Doi:10.4172/2327-5146.1000e110

Kelleni MT (2016): Simeprevir, Sofosbuvir and Ribavirin as First Line Therapy of HCV Infection, is it Justifiable Enough Basing on Safety and Efficacy. Gen Med (Los Angel) 4:e109. Doi:10.4172/2327-5146.1000e109

Mina T Kelleni (2016): Amyloid Antagonists: The Future of Type 2 Diabetes as Well as Several Neurodegenerative Diseases Treatments. Dia Obe Int Jo. 1(2): 000106.

Mina T Kelleni (2016): Cefotaxime Used as Paracetamol- Antibiotic Resistance in Developing Countries, A Global Upcoming Catastrophe Unless Urgently Addressed. Journal of Prevention & Infection Control 2(1): 14.

Mina T Kelleni, Salwa A Ibrahim and Aly M Abdelrahman (2016): Effect of captopril and telmisartan on methotrexate-induced hepatotoxicity in rats: impact of oxidative stress, inflammation and apoptosis. *Toxicol Mech Method*. DOI: 10.1080/15376516.2016.1191576. PMID: 27269004.

Q2 Journal, Impact Factor 3.2

Kelleni MT (2016) Chamomile Tea Potentials in Prevention and Amelioration of Type 2 Diabetes Mellitus. *J Diabetes Metab* 7:649. DOI:10.4172/2155-6156.1000649

Mina T. Kelleni, Entesar F. Amin, Aly M. Abdelrahman (2015): Effect of Metformin and Sitagliptin on Doxorubicin-induced Cardiotoxicity in Rats: Impact of Oxidative Stress, Inflammation and Apoptosis. *J Toxicol*, Article ID 424813. DOI: 10.1155/2015/424813. PMID: 26880912

Q2 Journal (Scopus), Impact Factor 2.9

Kelleni MT (2015) Pioglitazone and Sitagliptin: An Urgent Call for New Regulations Controlling all the Post Marketing Drug Safety Studies. *Endocrinol Metab Int J* 2(4): 00029. DOI: 10.15406/emij.2015.02.00029

Mina T Kelleni (2015) A Peculiar Juvenile Progressive Systemic Sclerosis Case Report: The Egyptian versus the International Approach of Treatment. *Gen Med (Los Angel)* S2:005. DOI:10.4172/2327-5146.1000S2-005

Kelleni MT (2015) Fludarabine Monotherapy Fails to Control a Case of Relapsing Non-Hodgkin's Lymphoma. *Gen Med (Los Angel)* 3:204. DOI:10.4172/2327-5146.1000204

Kelleni MT (2015) Together towards an early global detection of type 2 diabetes using a simplified metabolomics' test. *Integr Obesity Diabetes*. 1: DOI: 10.15761/IOD.1000121

Kelleni MT (2014) Pioglitazone: How Pharmacology Can be used Interchangeably with Mammonology in the Developing Countries? *J Diabetes Metab* 5 (8):411

Mohamed Ibrahim, **Mina Kelleni**, Ayman Geddawy (2013) Nonalcoholic fatty liver disease: Current and potential therapies. Life Sci. 7; 92(2):114-8. DOI: 10.1016/j.lfs.2012.11.004. PMID: 23159641

Q1 Journal, Impact Factor 6.1

Mohamed Ibrahim, Entesar Farghaly, Wafaey Gomaa, **Mina Kelleni**, Aly Mohamed Abdelrahman (2011) Nitro-aspirin is a potential therapy for nonalcoholic fatty liver disease. Eur J Pharm, 659: 289-295. DOI: 10.1016/j.ejphar.2011.03.016. PMID: 21453696

Q1 Journal, Impact Factor 5

Mohamed Ibrahim, Entesar Farghaly, Wafaey Gomaa, **Mina Kelleni**, Aly Abdelrahman (2010) Ezetimibe inhibits proinflammatory mediators involved in the pathogenesis of nonalcoholic fatty liver disease. Egypt. J. Med Sci, 31 (1): 247-269.

Medical Books Activities

Mina T Kelleni (2020): **Editor** of "Anticoagulation drugs - the Current State of the Art" book: ISBN: 978-1-78985-076-5; Print ISBN: 978-1-78985-075-8

Mina T Kelleni (2020): Introductory Chapter: Anticoagulant Therapy in Clinical Practice - Challenges and Wishes. Anticoagulation drugs - the Current State of the Art, Mina T. Kelleni: IntechOpen, DOI: 10.5772/intechopen.89869. ISBN: 978-1-78985-076-5; Print ISBN: 978-1-78985-075-8

Mina T. Kelleni and Mahrous Abdelbasset (2018): Drug Induced Cardiotoxicity: Mechanism, Prevention and Management. Cardiotoxicity, Wenying Tan. IntechOpen, DOI: 10.5772/intechopen.79611. ISBN: 978-1-78984-238-8; Print ISBN: 978-1-78984-237-1